Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapies
05/12/2020
Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman is sounding the alarm, according to a FiercePharma report.
While U.S. distribution channels for possible COVID-19 vaccines and therapies are adequate to meet patients’ needs, manufacturing capacity to fulfill those orders is “limited,” Regeneron CEO Len Schleifer told CNN’s “State of the Union” Sunday.